Live Breaking News & Updates on Gastaut Syndrome|Page 1

Stay updated with breaking news from Gastaut syndrome. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , Luis Sanay , Jeffreym Dayno , Epygenix Company Presentation , European Medicines Agency , Epygenix Therapeutics Inc , Exchange Commission , European Union , Share Repurchase Program , Harmony Biosciences Holdings Inc , Paragon Biosciences , Drug Administration , Its Growth Strategy , Advances Pitolisant Franchise , Extend Revenue Potential Beyond , Wake Leadership , Diversifies Into Rare , Net Revenue , First Quarter , New Drug Application , Idiopathic Hypersomnia Planned , Second Half , Track Toward Pediatric Exclusivity , Pediatric Narcolepsy , Franchise Revenue Potential Extended Beyond ,

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ...

WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year ....

United Kingdom , United States , Luis Sanay , Jeffreym Dayno , Epygenix Therapeutics Inc , Exchange Commission , Epygenix Company Presentation , Share Repurchase Program , European Union , European Medicines Agency , Harmony Biosciences Holdings Inc , Drug Administration , Paragon Biosciences , Net Revenue , First Quarter , New Drug Application , Idiopathic Hypersomnia Planned , Second Half , Track Toward Pediatric Exclusivity , Pediatric Narcolepsy , Franchise Revenue Potential Extended Beyond , Next Generation Formulations , Reports Positive Pharmacokinetic Data , Next Generation Formulation , Leadership Position , Highly Potent ,

Dravet syndrome treatment market size to increase by USD 575.14 million between 2022-2027, Technavio

/PRNewswire/ The Dravet Syndrome Treatment Market by Product, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been. ....

United Kingdom , United States , Stiripentol Diacomit , Jesse Maida , Drug Administration , European Medicines Agency , Dravet Foundation , Technavio Research , Dravet Syndrome Treatment Market , Distribution Channel , Regulatory Designations Propel Market Growth , Neuroene Therapeutic , Market Trends Point , Enhanced Treatment Efficacy , Persist Amid Promising Growth , Players Forge Ahead , Strategic Initiatives , Gastaut Syndrome , Lennox Gastaut Syndrome ,

Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan -March 26, 2024 at 03:06 am EDT

NEWS RELEASE

March 26, 2024

UCB Japan Obtained Additional Application of Fintepla®

for the Treatment of Seizures. ....

Bruxelles Capitale , Toru Nakai , Kanako Kikuchi , Zogenix Inc , Japan Co , Corporate Communications Dept , Ministry Of Health , Nippon Shinyaku Co Ltd , Obtained Additional Application , Seizures Associated , Gastaut Syndrome , Nippon Shinyaku , Oral Solution , Communications Dept ,